Atara Biotherapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 12, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 12, 2026
ATRA$8.10-1.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(In thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net income (loss) | $(4,145) | $38,010 |
| Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||
| Stock-based compensation expense | 749 | 4,209 |
| Depreciation and amortization expense | 29 | 1,795 |
| Accretion of liability related to sale of future revenues | 814 | 852 |
| Amortization (accretion) of investment premiums (discounts) | — | 259 |
| Non-cash operating lease expense | 185 | 3,950 |
| Loss on impairment of lease right-of-use asset | — | 4,130 |
| Other non-cash items, net | 49 | 770 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 1,253 | (7,393) |
| Inventories | — | 10,655 |
| Other current assets | (1,336) | 4,535 |
| Other assets | (15) | 8 |
| Accounts payable | 510 | (2,983) |
| Accrued compensation | (642) | (1,990) |
| Accrued research and development expenses | (41) | (6,201) |
| Other current liabilities | (166) | 3,493 |
| Deferred revenue | (32) | (79,109) |
| Operating lease liabilities | (285) | (3,238) |
| Other long-term liabilities | — | 110 |
| Net cash used in operating activities | (3,073) | (28,138) |
| Investing activities | ||
| Proceeds from maturities and sales of short-term investments | — | 17,199 |
| Net cash provided by investing activities | — | 17,199 |
| Financing activities | ||
| Proceeds from issuance of common stock through ATM facilities, net | 2,951 | — |
| Principal payments on finance lease obligations | — | (250) |
| Net cash provided by (used in) financing activities | 2,951 | (250) |
| Increase (decrease) in cash, cash equivalents and restricted cash | (122) | (11,189) |
| Cash, cash equivalents and restricted cash at beginning of period | 8,482 | 25,176 |
| Cash, cash equivalents and restricted cash at end of period | $8,360 | $13,987 |
| Non-cash financing activities | ||
| Issuance of pre-funded warrants in connection with HCRx Amendment | $1,672 | $— |
| Accrued costs related to ATM facility | $36 | $— |
| Supplemental cash flow disclosure | ||
| Cash paid for interest | $105 | $66 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.